<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515539</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-3103-01</org_study_id>
    <nct_id>NCT02515539</nct_id>
  </id_info>
  <brief_title>Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)</brief_title>
  <official_title>Early Feasibility Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transfemoral and Transapical Delivery Systems)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to generate early US feasibility data of the CardiAQ™
      Transcatheter Mitral Valve Implant System.

      The study will enroll patients with moderate to severe mitral valve regurgitation who are
      considered high risk for mortality and morbidity from conventional open-heart surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early feasibility study - multi-center, prospective, single-arm, and non-randomized study
      without concurrent or historical controls.

      The primary objective of the study is to generate early feasibility data for the CardiAQ™
      Transcatheter Mitral Valve Implant System with the Transfemoral and Transapical Delivery
      Systems for the treatment of moderate to severe mitral valve regurgitation in patients who
      are considered high risk for mortality and morbidity from conventional open-heart surgery.

      The secondary objectives of the study are to evaluate the long-term safety of the device and
      the effects of the device on performance, functional, quality of life parameters, and
      technical, device, procedural, and individual patient successes.

      The study is to be performed at a maximum of 5 investigational sites in the US.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Edwards Lifesciences terminated the IDE associated with this study. No patients enrolled.
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Major Adverse Event Rate</measure>
    <time_frame>30-Day</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Mitral Insufficiency</condition>
  <condition>Heart Valve Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>CardiAQ TMVI System (Transapical &amp; Transfemoral DS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardiAQ TMVI System (Transapical &amp; Transfemoral DS)</intervention_name>
    <description>CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System</description>
    <arm_group_label>CardiAQ TMVI System (Transapical &amp; Transfemoral DS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  NYHA Classification ≥ III

          -  Left Ventricular Ejection Fraction ≥ 30%

          -  Mitral Regurgitation ≥ Grade 3+

          -  Subject meets anatomical and eligibility criteria for the investigational device

        Exclusion Criteria:

          -  See Protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilson Szeto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Herrmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saibal Kar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Trento, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Mitral Valve Replacement</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Mitral Insufficiency</keyword>
  <keyword>Transapical</keyword>
  <keyword>Transfemoral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

